We hypothesized that women with lower extremity peripheral arterial disease (PAD) would have greater mobility loss and faster functional decline than men with PAD.
Lower extremity peripheral arterial disease (PAD) affects 8 million men and women in the U.S. (1) . Among older individuals, the prevalence of PAD is similar to or even slightly higher in women as compared with men (1-3). A previous cross-sectional study demonstrated that women with PAD have greater functional impairment and poorer lower extremity strength than men with PAD (4). However, little is known about sex differences in rates of functional decline or changes in calf muscle characteristics over time between men and women with PAD.
In this observational, longitudinal study, we compared rates of mobility loss, decline in 6-min walk performance, and decline in walking velocity between men and women with PAD at 4 years of follow-up. We also compared baseline measures of calf muscle characteristics and leg strength and changes in these muscle outcomes between men and women with PAD at 4 years of follow-up. We hypothesized that women with PAD would have greater mobility loss, faster functional decline, and more adverse changes in calf muscle characteristics over time compared with men with PAD. We further hypothesized that greater mobility loss and faster functional decline among women with PAD as compared with men with PAD is explained by more adverse muscle characteristics among women with PAD as compared with men with PAD.
Methods
Study overview. The Institutional Review Boards of Northwestern University and Catholic Health Partners Hospital approved the protocol. Participants gave written informed consent. Participants were in the WALCS (Walking and Leg Circulation Study) II cohort, a prospective, observational study designed to identify mechanisms of functional decline in PAD (5, 6) . Participants underwent baseline measures and returned annually for follow-up for up to 4 follow-up visits. Data collection took place between November 6, 2002 , and October 16, 2009 . Every effort was made to maximize follow-up by scheduling follow-up visits before or after their due date, if a participant was otherwise unable to return for follow-up testing. Participant identification. PAD participants were 59 years of age and older and were identified from among consecutive patients diagnosed with PAD in Chicago-area noninvasive vascular laboratories (5, 6) . A small number of PAD participants were identified from among consecutive patients in a large general internal medicine practice at Northwestern with a low ankle brachial index (ABI) at their study visit. PAD was defined as ABI Ͻ0.90 (2, 5, 6) . Absence of PAD was defined as ABI 0.90 or more and 1.30 or less (5, 6) .
Participation rates and exclusion criteria for the WALCS II cohort have been described and are summarized briefly here (6) . Patients with dementia were excluded because of their inability to answer questions accurately. Nursing home residents, wheelchair-bound patients, and patients with foot or leg amputations were excluded because they had severely impaired functioning at baseline. Non-English-speaking patients were excluded because investigators were not fluent in non-English languages. Patients with recent major surgery were excluded. ABI measurement. A hand-held Doppler probe (Nicolet Vascular Pocket Dop II, Nicolet Biomedical, Inc., Golden, Colorado) was used to obtain systolic pressures in the right and left brachial, dorsalis pedis, and posterior tibial arteries (5-7). Each pressure was measured twice. The ABI was calculated by dividing the mean of the dorsalis pedis and posterior tibial pressures in each leg by the mean of the 4 brachial pressures (7) . Zero values for the dorsalis pedis and posterior tibial pulses were set to missing for the ABI calculation. Average brachial pressures in the arm with highest pressure were used when 1 brachial pressure was higher than the opposite brachial pressure in both measurement sets and the 2 brachial pressures differed by 10 mm Hg or more in at least 1 measurement set, because in such cases, subclavian stenosis is possible (8) . The lowest leg ABI was used in analyses. Functional outcomes. Functional outcomes were assessed annually and consisted of mobility loss, becoming unable to walk for 6 min continuously without stopping, decline in 6-min walk performance of 20% or more, and average annual declines in 6-min walk performance, usual paced 4-m walking velocity, and fastest paced 4-m walking velocity (5,9). 6-min walk. Following a standardized protocol (9), participants walk up and down a 100-foot hallway for 6 min after instructions to cover as much distance as possible. The test administrator recorded whether the participant stopped during the 6-min walk. Participants who stopped at baseline were excluded from analyses of becoming unable to complete the 6-min walk without stopping. 4-m walking velocity. Walking velocity was measured with a 4-m walk performed at usual and fastest pace, based on a previous study (9, 10) . Each walk was performed twice. The faster walk in each pair was used in analyses (9, 10) . Mobility measures. At baseline and at each follow-up visit, participants were asked to indicate whether they could walk a quarter mile and whether they could climb up and down 1 flight of stairs: 1) on their own; 2) with assistance; or 3) not at all (5, 10) . Mobility loss was defined as becoming unable to walk up and down one flight of stairs or to walk a quarter mile without assistance among those without mobility limitations at baseline (5, 10) . Those unable to return for follow-up were interviewed by telephone for the mobility outcome measure. Calf muscle characteristics. Calf muscle measurements were assessed with computed tomography (CT) at baseline and at the 2-and 4-year follow-up visits using a CT scanner (LightSpeed, General Electric Medical Systems, Waukesha, Wisconsin) (5, 6) . Cross-sectional images of the calves measuring 2.5 mm were obtained at 66.7% of the distance from the distal to the proximal tibia (6, 7) . Cross-sectional images were analyzed using BonAlyse (BonAlyse Oy, Jyvaskyla, Finland), a software for processing CT images that identifies muscle tissue, fat, and bone (11) . The muscle outline was traced manually, excluding subcutaneous fat and bone. When quantifying muscle area, the BonAlyse software quantifies voxels within a range corresponding to muscle density (9 to 271 mg/cm 3 ) and excludes voxels corresponding to fat density (Ϫ270 to 8 mg/cm 3 ). Intramuscular fat is quantified by summing voxels corresponding to fat within muscle tissue. Cadaver studies demonstrate that these methods provide an estimate of muscle crosssectional area that is highly correlated with direct anatomic measures (12) . Because larger individuals require greater muscle mass to support their frame, muscle area was adjusted for the square of individual tibia length (5) . Muscle density measures the quantity of muscle per volume within the voxel range corresponding to muscle (9 to 271 mg/cm 3 ) and is a measure of muscle quality.
Isometric strength measures. Knee extension strength was measured at baseline and annually during follow-up using a computer-linked strength chair with a transducer placed for knee extension (Good Strength Chair, Metitur Oy, Jyvasklya, Finland) (13) . Data were collected electronically by computer over 6 s. Strength measurements using the Good Strength Chair have high test-retest reliability (Pearson product moment correlations: 0.88 to 0.96) (14) . Two trials were performed. Maximum strength was used in analyses (13) . Comorbidities. Comorbidities assessed at baseline were diabetes, angina, myocardial infarction, heart failure, cancer, chronic lung disease, lower extremity arthritis, spinal stenosis, spinal disk disease, and stroke (15) . Disease-specific algorithms that combine data from the patient report, medical record review, medications, laboratory values, and a questionnaire completed by the participant's primary care physician were used to verify and document baseline comorbidities other than knee and hip arthritis, based on criteria previously developed (15) . American College of Rheumatology criteria were used to document presence of knee and hip osteoarthritis (16, 17) . Other measures. Height and weight were measured at baseline. Body mass index (BMI) was calculated as weight in kilograms per height in square meters. Cigarette smoking history was determined with the patient report. At baseline, participants were asked to report the number of blocks they walked during the previous week. At each follow-up visit, we used the patient report, a primary care physician questionnaire, and medical record review to identify lower extremity revascularizations since the prior visit. Statistical analyses. Analyses of covariance was used to compare baseline clinical characteristics between men and women with PAD, adjusting for age. A priori, a p value Ͻ0.05 was considered statistically significant. For the outcomes of loss of the ability to walk continuously for 6 min without stopping, mobility loss, and a 20% or more decline in distance achieved in the 6-min walk test, Cox regression analyses were used to compare rates of each functional outcome between men and women with PAD, adjusting for confounders. We used PROC PHREG to perform these analyses and TIES equal to DISCRETE for the discrete time point in years. For the outcome of mobility loss, participants with mobility limitations at baseline were excluded. For the outcome of becoming unable to walk for 6 min continuously, participants unable to walk for 6 min without stopping at baseline were excluded. Person-time was calculated as the number of months from the baseline visit to the date of the most recent visit (last seen) or the date of the visit during which each functional outcome of interest was first reported, whichever came first. Participants who died before experiencing an outcome measure or who underwent lower extremity revascularization during follow-up were censored at the date of their last visit before these events. In these analyses, model I adjusted for age, race, ABI, BMI, smoking, comorbidities (diabetes, angina, myocardial infarction, heart failure, cancer, chronic lung disease, knee arthritis, hip arthritis, spinal stenosis, disk disease, and stroke), and physical activity. To determine whether sex differences in baseline calf muscle characteristics or knee extension strength may explain sex differences in functional decline, model I was repeated with additional adjustment for baseline measures of each calf characteristic, knee extension strength, and baseline 6-min walk performance, respectively. We tested the proportional hazards assumption for the 3 outcome measures using martingale residuals-based methods (18) . There were no significant deviations from the proportional hazards assumption.
Changes in continuous outcome measures, including functional performance (6-min walk distance and 4-m walking velocity), knee extension strength, and calf muscle characteristics were compared between men and women with PAD using a longitudinal or repeated-measures analysis of covariance and a mixed model approach. PROC MIXED in SAS software (SAS Institute, Inc., Cary, North Carolina) was applied for this procedure. The withinsubject correlations were modeled with a subject-specific random effect. The primary dependent variables for each analysis were the successive annual differences in each outcome of interest (i.e., the difference in 6-min walk distance between baseline and the first follow-up visit, between the first and second follow-up visit, between the second and third follow-up visit, and so on). Sex differences in decline for each continuous outcome were compared using an analysis of covariance, adjusting for baseline age, race, BMI, smoking, physical activity, comorbidities, and the corresponding prior year performance or muscle characteristic (model I). Analyses of average annual decline in 6-min walk performance or 4-m walking velocity were repeated with additional adjustment for each baseline calf muscle characteristic and baseline knee extension strength, respectively, to determine whether sex differences in functional decline could be explained by sex differences in baseline muscle characteristics. Analyses were performed using SAS statistical software (version 9.2, SAS Institute, Inc.).
Results
Four-hundred fifty-five participants in the WALCS II cohort had a baseline ABI of less than 0.90 and completed baseline calf muscle measures or underwent measurement of baseline knee extension strength. Of these, 70 (15%) did not meet inclusion criteria for any functional outcomes and 5 (1%) did not have data for at least 1 covariate measure. Of the 75 who did not meet inclusion criteria, 32 (42.7%) were women. Mean follow-up was 47 months (range 8 to 81 months).
The mean age Ϯ SD of the women was 76.0 Ϯ 8.1 years, and that of men was 74.2 Ϯ 7.7 years (p ϭ 0.024). Table 1 shows baseline characteristics of men and women with PAD, adjusting for age. Women with PAD included higher prevalences of African Americans, those with knee arthritis, 709 JACC Vol. 57, No. 6, 2011 McDermott et al. February 8, 2011:707-14 Sex Differences in Peripheral Arterial Disease and those with disc disease and lower prevalences of angina compared with men with PAD ( Table 1) . Adjusting for age, women walked fewer blocks per week and had poorer 6-min walk performance, smaller calf muscle area, lower calf muscle density, and poorer knee extension strength compared with men (Table 1) . PAD. Compared with men, women were more likely to become unable to walk for 6 min continuously, had greater mobility loss, and had greater average annual declines in 6-min walk distance and usual-paced 4-m walking velocity, adjusting for age, race, BMI, comorbidities, physical activity, smoking, prior year performance (6-min walk and walking velocity outcomes only), and ABI (Table 2) . Compared with men, women had less annual decline in calf muscle area, less increase in calf muscle percent fat, and less decline in knee extension isometric strength adjusting for age, race, BMI, comorbidities, physical activity, smoking, prior year calf muscle or strength measurement, and ABI (Table 2) .
To determine whether baseline sex differences in functional performance might have influenced our findings regarding mobility loss, becoming unable to walk for 6 min continuously, and 20% or more decline in 6-min walk performance, we repeated analyses for these outcomes after additionally adjusting for baseline 6-min walk performance. After additional adjustment for baseline 6-min walk performance, associations of female sex with faster decline were attenuated. Hazard ratios for mobility loss, becoming unable to walk for 6 min continuously, and 20% or more decline in 6-min walk distance were 1.35 (95% confidence interval: 0.77 to 2.36, p ϭ 0.288), 1.70 (95% confidence interval: 0.94 to 3.09, p ϭ 0.088), and 1.27 (95% confidence interval: 0.82 to 1.97, p ϭ 0.289), respectively. These findings suggest that baseline sex differences in functional performance may contribute to higher rates of decline in these 3 outcomes among women as compared with men with PAD.
Associations of sex with functional decline, with and without adjustment for baseline calf muscle area, are shown in Table 3 . Data in Table 3 are limited to participants with baseline calf muscle area data. In this subset of 369 participants, women had a higher rate of becoming unable to walk for 6 min continuously during follow-up, a higher rate of mobility loss, and greater decline in the usual-paced 4-m walking velocity, adjusting for age, race, BMI, comorbidities, physical activity, smoking, prior year performance (for analyses of average annual declines only), and ABI (Table 3 , base model). These associations of female sex with faster functional decline were attenuated and no longer statistically significant after additional adjustment for baseline calf muscle area (Table 3) . Similarly, the association of female sex with greater decline in usual-paced walking velocity was no longer statistically significant after the base model was adjusted additionally for calf muscle density (Ϫ0.035 m/s/year for women vs. Ϫ0.024 m/s/year for men, p ϭ 0.052). However, remaining significant associations of female sex with functional decline were not attenuated and remained statistically significant after additional adjustment of the base model for calf muscle density. Similarly, the significant associations of female sex with faster functional 
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Sex Differences in Peripheral Arterial Disease decline were not attenuated and remained statistically significant after additional adjustment of the base model for calf muscle percent fat (data not shown). Together, these findings suggest that lower baseline calf muscle area among women may mediate the association of female sex with faster functional decline among participants with PAD. In contrast, these findings suggest that baseline sex differences in calf muscle percent fat do not mediate associations of female sex with faster functional decline. Associations of sex with functional decline, with and without adjustment for baseline knee extension isometric strength, are shown in Table 4 . Analyses are limited to participants with baseline knee extension strength data (n ϭ 285). In this subset, women had a higher incidence of becoming unable to walk for 6 min continuously during follow-up and faster declines in 4-m walking velocity at usual and fastest pace, adjusting for age, race, BMI, comorbidities, physical activity, smoking, prior year performance (6-min walk and walking velocity outcomes only), and ABI (Table 4 , base model). Most of these associations were attenuated after additional adjustment for baseline knee extension strength (Table 4 ). The association of female sex with faster decline in walking velocity remained statistically significant even after adjustment for baseline knee extension strength (Table 4 ). These findings suggest that baseline higher knee extension strength in men as compared with women may mediate the association of female sex with faster functional decline compared with men.
Discussion
Our data shows that at 47 months of follow-up, women with PAD were more likely to become unable to walk for 6 min continuously, had a higher incidence of mobility loss, and had faster declines in 6-min walk distance and usualpaced walking velocity compared with men with PAD. These findings were independent of potential confounders including sex differences in comorbid disease prevalence and physical activity. However, after adjustment for baseline sex differences in functional performance, the associations of female sex with becoming unable to walk for 6 min continuously and mobility loss were attenuated and no longer statistically significant. These latter findings suggest that the poorer functional performance at baseline among women compared with men resulted in women being closer at baseline to the thresholds for the outcomes of mobility loss and becoming unable to walk for 6 min continuously as compared with men.
At baseline, women had smaller calf muscle area, lower calf muscle density, and poorer knee extension strength as compared with men. When sex differences in functional decline were adjusted for baseline sex differences in calf muscle area and knee extension strength, associations of female sex with faster functional decline were attenuated and no longer statistically significant. These findings suggest that lower calf muscle area and reduced knee extension strength in women at baseline may explain in part the faster rates of functional decline in women with PAD as compared with men with PAD. Although men had more favorable calf muscle characteristics and greater knee extension strength at baseline, calf muscle area and knee extension strength declined more rapidly in men than in women over time, whereas calf muscle percent fat increased more rapidly in men. Thus, men with PAD experienced more rapid deterioration in lower extremity muscle characteristics and strength than women. Our findings suggest that men with PAD have greater lower extremity muscle reserve than women, but are more susceptible to loss of favorable muscle characteristics and function compared with women. The greater baseline muscle reserve among men with PAD may protect them against functional decline, relative to women with PAD.
Mechanisms for the faster rates of decline in knee extension strength and more rapid progression of adverse changes in calf muscle characteristics among men as compared with women with PAD could not be discerned from the current study. However, a previous longitudinal study of participants without PAD demonstrated that loss of muscle mass was approximately twice as rapid in men as compared with women (19) . Declining levels of testosterone in older men may contribute to declines in skeletal muscle characteristics and performance in men over time (19 -21) .
Although PAD is common among both men and women in older populations (1-3), little is known about sex differences in functional decline among patients with PAD. Identifying sex differences in lower extremity outcomes among patients with PAD will help clinicians to provide prognostic information and to make optimal therapeutic decisions for patients with PAD. Our findings demonstrate that sex differences in functional decline were greatest for the outcomes of mobility loss and becoming unable to walk for 6 min continuously than for the continuous outcome measures of distance achieved in the 6-min walk and 4-m walking velocity. Our results suggest that because of their poorer baseline performance, women were closer at baseline to the outcomes of mobility loss and becoming unable to walk for 6 min continuously compared with men with PAD.
Among PAD participants in our original WALCS cohort, we previously reported no sex differences in declines in 6-min walk distance or walking velocity at 3 years of follow-up (22) . At 4 years of follow-up, women had a greater decline in walking velocity compared with men, although the findings did not achieve statistical significance (p ϭ 0.052). As compared with this prior study, the current study consists of the WALCS II cohort, assessed all outcomes through a mean follow-up of 47 months, and assessed changes in CT-measured muscle characteristics, muscle strength, and additional functional outcomes compared with the previous study (22) . Study limitations. First, data are observational. Observed associations should not be construed as causal. Second, participants were recruited from Chicago-area academic medical centers. Findings may not be generalizable to PAD patients outside of academic medical centers. Third, residual confounding from the older age of women with PAD as compared with men with PAD may have influenced our finding that women with PAD have faster rates of functional decline than men with PAD. However, despite this potential for residual confounding, our results still demonstrated that men had more rapid adverse changes in calf muscle characteristics and muscle strength over time. Fourth, our analyses included multiple sex comparisons. A priori, we selected p Ͻ 0.05 as the level of statistical significance. Although not all comparisons were statistically significant, our findings consistently demonstrated that functional decline was greater in women than in men. Similarly, adverse changes in muscle characteristics consistently occurred more rapidly in men than in women.
Conclusions
Women with PAD have faster rates of functional decline than men with PAD. These differences seem to be related in part to more favorable calf muscle characteristics and lower extremity strength at baseline in men as compared with women with PAD. A previous study demonstrated that lower extremity strength training improves treadmill walking performance and quality of life in participants with PAD (23) . Further study is needed to determine whether interventions to increase calf muscle area, to improve lower extremity strength among women with PAD, or both can slow their faster functional decline as compared with men with PAD.
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